Elsevier

Atherosclerosis

Volume 184, Issue 2, February 2006, Pages 446-447
Atherosclerosis

Letter to the Editor
Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis

https://doi.org/10.1016/j.atherosclerosis.2005.10.028Get rights and content

References (12)

There are more references available in the full text version of this article.

Cited by (63)

  • TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis

    2019, iScience
    Citation Excerpt :

    Much of TRAIL biology has focused on its ability to kill cancer cells. However, low TRAIL concentrations positively associate with CVD in people (Schoppet et al., 2006), suggesting a role that goes beyond that of killing. Indeed, non-apoptotic functions, including stimulation of cell survival, proliferation, and migration, particularly in vascular cells (Azahri et al., 2012; Cartland et al., 2014, 2017; Chan et al., 2010; Di Bartolo et al., 2015; Harith et al., 2015; Kavurma et al., 2008a; Secchiero et al., 2004a, 2004b), and even cancer cells, (Lancaster et al., 2003; Secchiero et al., 2005) have been described.

  • Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels areassociated with acute ischemic stroke severity

    2015, Atherosclerosis
    Citation Excerpt :

    On the other hand, several studies have demonstrated possible anti-inflammatory and anti-atherogenic activity in vitro and in vivo [4,5,20]. The results of previous clinical studies addressing the relationship between low serum TRAIL and cardiovascular diseases can be explained by the anti-inflammatory property of TRAIL [6–10]. Furthermore, our findings of low serum TRAIL level with the increase of acute ischemic stroke severity also could be additional data, which support the anti-inflammatory role of TRAIL.

  • TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling

    2014, Atherosclerosis
    Citation Excerpt :

    Furthermore, in vivo studies have found that administration of rTRAIL to diabetic ApoE−/− mice resulted in the stabilization of atherosclerotic plaque by increasing vascular smooth muscle cell (VSMC) content, and reducing overall lesion size [5,6]. Of note, 3 recent in vivo studies have shown that the serum levels of TRAIL are markedly reduced in diabetic patients [7,8] and patients with atherosclerosis [9]. It is also known that diabetes is a risk-factor for cardiovascular disease, and endothelial dysfunction is an early physiological event in cardiovascular disease [10,11].

View all citing articles on Scopus
View full text